With this comes the ability to predict the risk of disease, such as the presence of TET2, SRSF2, and ASXL mutations pointing toward the development of CMML, or the poor prognosis of MDS/MPN NOS associated with TP53 mutations. The gene discussed is TP53; the disease is chronic myelomonocytic leukemia.